Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic
Rhea-AI Summary
Anteris Technologies Global Corp (NASDAQ: AVR) announced a proposed public offering of $200.0 million of common stock with a 30-day underwriter option for an additional $30.0 million. Concurrently, Anteris agreed to a private placement with Medtronic for up to $90.0 million of shares at the public offering price, subject to a minimum purchase equal to 16.0% and a maximum of 19.99% of outstanding shares after the Offering. Completion of Medtronic's Private Placement is contingent on completion of the Offering; the Offering is not contingent on the Private Placement.
Proceeds, together with existing cash, are intended to fund the PARADIGM pivotal trial for the DurAVR THV, manufacturing expansion, R&D for v2vmedtech, working capital, and general corporate purposes. Barclays, Wells Fargo Securities and Cantor are joint book-runners; Wells Fargo is placement agent for the private placement.
Positive
- Proposed capital raise of $200M plus up to $30M option
- Strategic private investment of up to $90M from Medtronic
- Proceeds earmarked to fund PARADIGM pivotal trial for DurAVR THV
- Planned expansion of manufacturing capabilities
Negative
- Potential shareholder dilution from up to $320M primary raise (including option and Medtronic)
- Medtronic stake could reach 19.99%, affecting ownership structure
- Private Placement completion is contingent on the Offering, creating execution risk
- Underwriters may engage in stabilizing activities, which can affect trading
Key Figures
Market Reality Check
Peers on Argus
AVR was up 9.42% pre-announcement, while close peers showed mixed moves: KRMD -2.65%, NYXH -2.19%, MBOT +1.90%, INFU +2.81%, UTMD +1.36%. This points to stock-specific dynamics rather than a unified sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 17 | Clinical data update | Positive | -3.3% | Reported 30-day outcomes in 100 DurAVR THV patients with strong safety metrics. |
| Nov 12 | Quarterly earnings | Positive | -2.6% | Q3 2025 update highlighting PARADIGM progress, regulatory wins, and cash usage details. |
| Nov 03 | Regulatory approval | Positive | -3.1% | FDA approval to initiate PARADIGM global IDE pivotal trial for DurAVR THV. |
| Oct 28 | Clinical outcomes data | Positive | -7.8% | One-year pooled DurAVR THV outcomes in small annuli patients with no valve-related mortality. |
| Oct 27 | Trial enrollment update | Positive | +4.6% | First patients successfully treated in global PARADIGM pivotal trial for DurAVR THV. |
Recent clinically and regulatorily positive updates often saw negative price reactions, suggesting a tendency for the stock to sell off on good news.
Over the last few months, Anteris has focused on DurAVR® THV and the global PARADIGM trial. Key milestones included first patients treated on Oct 27, favorable one‑year hemodynamic data on Oct 28, FDA approval for the pivotal trial on Nov 3, and 30‑day pooled outcomes in 100 patients on Nov 17. A Q3 2025 update on cash usage and trial scaling followed on Nov 12. Despite generally positive clinical and regulatory tone, four of five events triggered negative 24‑hour moves, framing today’s capital-raising and strategic investment within a history of volatile post-news trading.
Market Pulse Summary
This announcement combines a sizable equity raise with a strategic investment from Medtronic, pairing balance sheet expansion with industry validation. The company plans to fund PARADIGM trial execution, manufacturing expansion, and R&D, building on recent clinical and regulatory milestones in 2025. Investors may track final deal terms, the size of Medtronic’s stake between 16.0% and 19.99%, and progress of DurAVR® THV pivotal enrollment to assess how effectively new capital translates into value creation.
Key Terms
underwritten public offering financial
private placement financial
registration statement regulatory
prospectus supplement regulatory
AI-generated analysis. Not financial advice.
MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that it is offering to sell, subject to market and other conditions,
In addition, pursuant to a stock purchase agreement, dated January 20, 2026, Anteris has agreed to sell to Medtronic plc (through a wholly owned subsidiary) in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), and at a price per share equal to the public offering price in the Offering, up to
Anteris intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents and the net proceeds from the Private Placement, to support the next stage of growth and advance execution of the Company’s clinical strategy. This includes ongoing recruitment and study execution of the DurAVR® Transcatheter Heart Valve (“DurAVR® THV”) global pivotal trial for patients with severe aortic stenosis (the “PARADIGM Trial”) and expansion of manufacturing capabilities. In addition, a portion of the proceeds is expected to fund ongoing research and development for v2vmedtech, inc., with the balance allocated to working capital and other general corporate purposes determined from time to time.
Barclays, Wells Fargo Securities and Cantor are acting as joint book-running managers for the Offering. Barrenjoey Markets Pty Limited is acting as financial advisor in connection with the Offering to investors in Asia-Pacific and certain other jurisdictions outside of the United States and Canada. Wells Fargo Securities is acting as sole placement agent in connection with the private placement of Anteris’ shares to Medtronic.
The shares of common stock in the public offering are being offered by the Company pursuant to a shelf registration statement on Form S-3 (the “Form S-3 Registration Statement”) that was filed with the Securities and Exchange Commission (the “SEC”) and declared effective on January 8, 2026. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the Offering have been or will be filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the Offering may be obtained, when available, from: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847 or by e-mail at barclaysprospectus@broadridge.com; Wells Fargo Securities, LLC, 90 South 7th Street, Minneapolis, MN 55402, by telephone at (800) 645-3751 (option #5), or by email at WFScustomerservice@wellsfargo.com; or Cantor Fitzgerald & Co., by mail at Attention: Capital Markets, 110 East 59th Street, New York, NY 10022, or by email at prospectus@cantor.com.
The shares of common stock being offered and sold in the Private Placement have not been registered under the Securities Act or any state’s securities laws. Accordingly, such securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. The prospectus supplement and the accompanying prospectus related to the Offering are not an offer to sell or a solicitation of an offer to buy any securities in connection with the Private Placement.
This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation or sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. As disclosed in the preliminary prospectus supplement related to the Offering, the underwriters may engage in stabilizing actions or related activities in connection with the Offering.
About Anteris
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
Anteris’ lead product, the DurAVR® THV, was designed in collaboration with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. The safety and efficacy of the DurAVR® THV are being evaluated in the PARADIGM Trial (NCT07194265), with the first patients enrolled and implanted with the DurAVR® THV in Denmark during the fourth quarter of 2025.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, any statements regarding the Offering and the Private Placement, the anticipated use of the net proceeds of the Offering and the Private Placement, and that the underwriters may engage in stabilizing actions or related activities in connection with the Offering. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in the Form S-3 Registration Statement and the preliminary prospectus supplement and accompanying prospectus related to the Offering. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, the Company does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
| For more information: | ||
| Investor Relations | Investor Relations (US) | |
| investors@anteristech.com | mchatterjee@bplifescience.com | |
| Debbie Ormsby | Malini Chatterjee, Ph.D. | |
| Anteris Technologies Global Corp. | Blueprint Life Science Group | |
| +61 1300 550 310 | +61 7 3152 3200 | +1 917 330 4269 | |
FAQ
What size public offering did Anteris (AVR) announce on January 20, 2026?
How much is Medtronic investing in Anteris (AVR) and what ownership could it attain?
What will Anteris (AVR) use the net proceeds from the offering and private placement for?
Is Medtronic's private placement to Anteris (AVR) conditional?
Who are the lead underwriters for Anteris (AVR)'s offering?
Will the offering shares be registered and where can investors find the prospectus for AVR?
